Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Breast Neoplasms 10163Neoplasms 7801Carcinoma, Non-Small-Cell Lung 5744Prostatic Neoplasms 5016Colorectal Neoplasms 4588Lung Neoplasms 3716Leukemia, Myeloid, Acute 3097Neoplasm Metastasis 3074Multiple Myeloma 3073Pancreatic Neoplasms 2837Melanoma 2646Lymphoma 2569Ovarian Neoplasms 2565Carcinoma, Hepatocellular 2473Stomach Neoplasms 2325Recurrence 2221Head and Neck Neoplasms 2095Precursor Cell Lymphoblastic Leukemia-Lymphoma 2084Lymphoma, Non-Hodgkin 2055Leukemia 2011Brain Neoplasms 1899Glioblastoma 1791Colonic Neoplasms 1790Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1714Uterine Cervical Neoplasms 1684Lymphoma, Follicular 1651Squamous Cell Carcinoma of Head and Neck 1649Lymphoma, Large B-Cell, Diffuse 1596Carcinoma, Renal Cell 1574

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bladder Adenocarcinoma × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡